Imunon, Inc. Interest Expense
Imunon, Inc. (IMNN) reported Interest Expense of $197.08 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-28.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2024-05-13
- Imunon, Inc. interest expense for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Imunon, Inc. interest expense for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Imunon, Inc. interest expense for the quarter ending 2023-06-30 was $37.09K, a 64.68% decline year-over-year.
- Imunon, Inc. interest expense for the quarter ending 2023-03-31 was $159.99K.
- Imunon, Inc. interest expense for fiscal 2023 was $197.08K, a 96.08% decline from fiscal 2022.
- Imunon, Inc. interest expense for fiscal 2022 was $5.03M, a 782.40% increase from fiscal 2021.
- Imunon, Inc. interest expense for fiscal 2021 was $569.88K, a 55.90% decline from fiscal 2020.
- Imunon, Inc. interest expense for fiscal 2020 was $1.29M.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $0.00 derived: sum of 2 quarters · filed 2024-03-28 | $37.09K derived: sum of 3 quarters · filed 2024-03-28 | $197.08K 10-K · filed 2024-03-28 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $37.09K derived: sum of 2 quarters · filed 2023-11-14 | $197.08K 10-Q · filed 2023-11-14 | $347.39K derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-06-30 | $37.09K 10-Q · filed 2023-08-10 | $197.08K 10-Q · filed 2023-08-10 | $347.39K derived: sum of 3 quarters · filed 2024-05-13 | $474.42K derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-03-31 | $159.99K 10-Q · filed 2024-05-13 | $310.30K derived: sum of 2 quarters · filed 2024-05-13 | $437.32K derived: sum of 3 quarters · filed 2024-05-13 | $542.35K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $150.31K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $277.34K derived: sum of 2 quarters · filed 2024-03-28 | $382.36K derived: sum of 3 quarters · filed 2024-03-28 | $5.03M 10-K · filed 2024-03-28 |
| 2022-09-30 | $127.03K 10-Q · filed 2023-11-14 | $232.05K derived: sum of 2 quarters · filed 2023-11-14 | $4.88M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $105.02K 10-Q · filed 2023-08-10 | $4.75M 10-Q · filed 2023-08-10 | ||
| 2021-12-31 | $95.52K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $191.04K derived: sum of 2 quarters · filed 2023-03-30 | $412.27K derived: sum of 3 quarters · filed 2023-03-30 | $569.88K 10-K · filed 2023-03-30 |
| 2021-09-30 | $95.52K 10-Q · filed 2022-11-14 | $316.75K derived: sum of 2 quarters · filed 2022-11-14 | $474.36K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $221.23K 10-Q · filed 2022-08-15 | $378.84K 10-Q · filed 2022-08-15 | ||
| 2020-12-31 | $1.29M 10-K · filed 2022-03-31 | |||
| 2012-12-31 | $359.41K 10-K · filed 2013-03-18 | |||
| 2011-12-31 | $501.86K 10-K · filed 2013-03-18 | |||
| 2010-12-31 | $31.52K 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |